Skip to Content

Join the 'Renal Cell Carcinoma' group to help and get support from people like you.

Renal Cell Carcinoma News

Related terms: Adenocarcinoma of renal cells, Cancer, Hypernephroma, Cancer, Kidney, Cancer, Renal, Cancer, Renal Cell Carcinoma, Hypernephroma, Kidney Cancer, Renal Cancer

Exelixis Announces FDA Approval of Cabometyx (cabozantinib) for Patients with Advanced Renal Cell Carcinoma

Posted 3 days ago by Drugs.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 25, 2016-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved Cabometyx (cabozantinib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. RCC is the most common form of kidney cancer in adults. Cabometyx, which was granted Fast Track and Breakthrough Therapy designations by the FDA, is the first therapy to demonstrate in a phase 3 trial for patients with advanced RCC, robust and clinically meaningful improvements in all three key efficacy parameters — overall survival, progression-free survival and objective response rate. “With today’s announcement, patients with previously treated advanced kidney cancer now have a new option, the first and only approved product demonstrated to help patients live longer w ... Read more

Related support groups: Renal Cell Carcinoma, Cabozantinib, Cabometyx

Drug Seems to Extend Survival for Advanced Melanoma Patients

Posted 12 days ago by Drugs.com

MONDAY, April 18, 2016 – More than one-third of advanced melanoma patients were still alive five years after starting therapy with the cancer drug nivolumab (Opdivo), researchers are reporting. "In 2012, we saw some very promising early evidence that this drug could not only cause the regression of very advanced cancer in patients with melanoma, lung or kidney cancers that had not responded to other forms of therapy, but we also saw that these responses appeared to be very durable," said lead researcher Dr. Suzanne Topalian. She is a professor of surgery and oncology at Johns Hopkins University School of Medicine, in Baltimore. Opdivo was approved for the treatment of advanced melanoma by the U.S. Food and Drug Administration in 2014. The results of this follow-up study, funded by Bristol-Myers Squibb, which makes Opdivo, were to be presented Sunday at the American Association for ... Read more

Related support groups: Lung Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Melanoma, Small Cell Lung Cancer, Melanoma - Metastatic, Opdivo, Wilms' Tumor, Nivolumab

Certain Biopsy Method Tied to Better Outcomes After Kidney Cancer

Posted 10 Mar 2016 by Drugs.com

THURSDAY, March 10, 2016 – A type of lab test called a "core-needle biopsy," performed on tissue taken from a mass on a kidney, may be better for certain kidney cancer patients, new research suggests. The study involved people with a renal (kidney) cell carcinoma – the most common type of kidney cancer in adults. Researchers led by Dr. Rosaleen Parsons, of Fox Chase Cancer Center in Philadelphia, noted that incidence and death rates of the disease have climbed in recent decades. But they added that so-called "image-guided" core-needle biopsy of kidney masses is increasingly being used to determine the best treatment approaches for individual patients. In their study, Parsons' team researchers tracked outcomes for patients who collectively underwent 374 kidney mass biopsies between 1999 and 2015. Core-needle biopsy – meaning that a tiny amount of tissue is removed using a hollow ... Read more

Related support groups: Cancer, Renal Failure, Renal Cell Carcinoma, Chronic Kidney Disease, Diagnosis and Investigation

Is Type 1 Diabetes Linked to Raised Risk of Certain Cancers?

Posted 2 Mar 2016 by Drugs.com

TUESDAY, March 1, 2016 – Having type 1 diabetes may raise the risk of some cancers, but lower the risk of others, a new study suggests. A higher risk was seen for cancers of the stomach, liver, pancreas, endometrium, ovary and kidneys. But a reduced risk was seen for prostate and breast cancers, researchers reported. In type 1 diabetes, the body cannot produce the hormone insulin, which helps regulate blood sugar levels. People with type 1 diabetes must be treated with insulin to survive. The good news from this study, said researcher Sarah Wild, is that it doesn't seem that insulin treatment is responsible for an increased risk of some cancers, which has been a concern. "This pattern of cancer risk [seen in the study] is similar to that seen for people with type 2 diabetes and people who are overweight," said Wild, a professor of epidemiology at the University of Edinburgh in the ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Diabetes, Type 1, Renal Cell Carcinoma, Ovarian Cancer, Pancreatic Cancer, Diabetes Mellitus, Stomach Cancer, Wilms' Tumor

Targeted Drug Shows Promise Against Advanced Kidney Cancer

Posted 6 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 6, 2016 – A targeted cancer drug appears to be effective against advanced kidney cancer, although its side effects may keep it from becoming widely used, researchers report. The drug, cabozantinib, proved more effective across-the-board in kidney cancer patients than another targeted drug called everolimus, said lead researcher Dr. Bernard Escudier. He is chair of the genitourinary oncology committee at the Institut Gustave Roussy in Villejuif, France. Overall, cabozantinib provided "almost a 50 percent improvement in progression-free survival" over everolimus, Escudier said. Cabozantinib works by interrupting several different cellular processes that help cancer grow and spread, Escudier explained. Unfortunately, that widespread approach also creates worrisome toxic side effects, he added. "Based on this multi-targeted action, we have quite a lot of side effects. ... Read more

Related support groups: Cancer, Renal Failure, Renal Cell Carcinoma, Chronic Kidney Disease, Solid Tumors, Urinary Tract Cancer, Cometriq, Cabozantinib, Urinary Tract Tumors

FDA Approves Opdivo to Treat Metastatic Renal Cell Carcinoma

Posted 23 Nov 2015 by Drugs.com

November 23, 2015 – The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy. “Opdivo provides an important therapy option for patients with renal cell carcinoma,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “It is one of few therapies that have demonstrated the ability to extend patients’ survival in treating this disease.” Torisel (temsirolimus), approved in 2007, is the only other FDA-approved therapy that has demonstrated overall survival in renal cell cancer. Renal cell carcinoma is the most common form of kidney cancer in adults and forms in the tissues of the kidney that make urine. The National Cancer Institute estimates 61,560 ... Read more

Related support groups: Renal Cell Carcinoma, Opdivo, Nivolumab

Barbecued, Pan-Fried Meat May Boost Kidney Cancer Risk

Posted 9 Nov 2015 by Drugs.com

MONDAY, Nov. 9, 2015 – Cooking meats at high temperatures, as in barbecuing or pan-frying, may increase the risk for kidney cancer, a new study suggests. The World Health Organization warned last month that processed meats – including bacon, hot dogs and sausages – can cause colon cancer. Red meats were also associated with higher risk. The new study looked specifically at kidney cancer, which is increasing in the United States and other developing nations. "This study, and others like it, suggest that the way we cook our meat could potentially impact kidney cancer risk," said lead researcher Dr. Xifeng Wu, a professor in the department of epidemiology at the University of Texas MD Anderson Cancer Center in Houston. "Limit the amount of time the meat is cooked at really high temperatures or over an open flame resulting in burning, smoking, or charring of the meat," Wu suggested. ... Read more

Related support groups: Renal Cell Carcinoma

New Immune-Focused Drug Shows Promise Against Advanced Kidney Cancer

Posted 25 Sep 2015 by Drugs.com

FRIDAY, Sept. 25, 2015 – A new drug that harnesses the power of the immune system to fight tumors appears to help people battling advanced kidney cancer, a new study finds. The drug, Opdivo (nivolumab), outperformed a standard chemotherapy, Afinitor (everolimus), in terms of shrinking tumors and boosting patient survival, the study found. The study was funded by Bristol-Myers Squibb, which makes Opdivo. It was to be presented Friday at the European Cancer Congress in Vienna, and is being published simultaneously in the New England Journal of Medicine. The new findings "are significant and clinically meaningful to patients and health care professionals alike," senior researcher Dr. Padmanee Sharma, of the University of Texas M.D. Anderson Cancer Center in Houston, said in a meeting news release. Sharma, a professor in the departments of genitourinary medical oncology and immunology, ... Read more

Related support groups: Renal Cell Carcinoma, Afinitor, Opdivo, Wilms' Tumor

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Arimidex, Femara, Tretinoin, Fluorouracil, Gleevec, Lupron Depot, Lung Cancer, Rituxan, Colorectal Cancer, Zoladex

Smoking Ups Risk of Complications From Urologic Cancers: Study

Posted 15 May 2015 by Drugs.com

FRIDAY, May 15, 2015 – Current and former smokers have more complications from major surgery for some urology-related cancers, according to new research. But even though former smokers have a higher risk of complications than non-smokers, the study also found that quitting smoking for as little as a year before surgery could "significantly" improve the outcomes of surgery. "These findings should provide motivation for all patients to quit smoking before undergoing major surgery. It's clear that they can expect better results with fewer complications if they do," Dr. Akshay Sood, a urologist and researcher at Henry Ford Hospital's Vattikuti Urology Institute, said in a hospital news release. The researchers focused on just over 9,000 patients who underwent surgery for cancers of the prostate, bladder or kidney from 2005 to 2011. They found that smokers were more likely to suffer from ... Read more

Related support groups: Smoking, Renal Cell Carcinoma, Bladder Cancer

Urine Test Shows Promise for Early Diagnosis of Kidney Cancer

Posted 20 Mar 2015 by Drugs.com

FRIDAY, March 20, 2015 – A urine test might someday become a much-needed early detection test for kidney cancer, a new study suggests. "This research is very important and a significant finding, because we do not have a good screening mechanism for kidney cancer," said one expert, Dr. Ketan Badani, professor of urology at the Icahn School of Medicine in New York City. The study was led by Dr. Evan Kharasch, professor of anesthesiology at Washington University School of Medicine. His team said that kidney cancer patients whose disease is diagnosed before the tumor spreads have an 80 percent survival rate. However, if the cancer is not spotted until after it has spread, 80 percent of patients die within five years. According to the researchers, finding the disease early – before it has spread – has remained a major challenge. "The most common way that we find kidney cancer is as an ... Read more

Related support groups: Renal Cell Carcinoma

Targeted Drugs Among Successes Against Cancer, Says New Report

Posted 16 Sep 2014 by Drugs.com

TUESDAY, Sept. 16, 2014 – About 14.5 million U.S. cancer survivors are alive today, compared to just 3 million in 1971, the American Association for Cancer Research reported Tuesday. These individuals amount to 4 percent of the population and include nearly 380,000 survivors of childhood cancer, according to the association's annual progress report. The paper outlines advances in prevention, identification, research and treatment of cancer and details some of the challenges ahead. But these numbers can be somewhat misleading unless they take into account advances in identifying cancers earlier, said Dr. Otis Brawley, chief medical officer of the American Cancer Society. Survival rates refer to how long a person lives with cancer (including in remission) while mortality rates refer to the death rate, but survival will be longer if the cancer is found earlier, even if the person dies at ... Read more

Related support groups: Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma, Skin Cancer, Pancreatic Cancer, Endometrial Cancer, Stomach Cancer, Gastric Cancer, Ceritinib, Zykadia

Kidney and Thyroid Cancer Rates Up Among U.S. Children, Study Finds

Posted 8 Sep 2014 by Drugs.com

MONDAY, Sept. 8, 2014 – Although the overall rate of cancer in American children and teens remained stable during the last decade, rates of thyroid cancer and kidney cancer seemed to be on the rise, a new study says. The rate of thyroid cancer saw annual increases of nearly 5 percent and a specific type of kidney cancer, called renal carcinoma, had average increases of 5.4 percent per year, according to the study. The researchers also found that cancer rates among black children and teens increased 1.3 percent per year. But one doctor not involved with the study said the finding could be a statistical "fluke." "It's scary to see an increase, but these cancers are overall very rare and the increases very small," said lead researcher Dr. David Siegel, a pediatric hematology/oncology fellow at Children's Healthcare of Atlanta. "We don't want to give a message that's alarming," he said. ... Read more

Related support groups: Renal Cell Carcinoma, Thyroid Cancer

New Cancer Classification System Might Boost Patient Outcomes

Posted 7 Aug 2014 by Drugs.com

THURSDAY, Aug. 7, 2014 – Changes to the way cancers are classified could lead to more accurate diagnoses and perhaps more effective treatments in about one in 10 cancer patients, new research suggests. Typically, cancers are categorized according to the tissue in which they originated, such as breast, bladder or kidney cancer. But tissues are composed of different types of cells. In this study, researchers who analyzed more than 3,500 tumor samples of 12 different cancer types concluded that defining tumors by their cellular and molecular features, rather than by the tissues in which they originated, would improve diagnoses in about 10 percent of cancer cases. "This genomic study not only challenges our existing system of classifying cancers based on tissue type, but also provides a massive new data resource for further exploration, as well as a comprehensive list of the molecular ... Read more

Related support groups: Cancer, Breast Cancer, Renal Cell Carcinoma, Bladder Cancer

Type of Kidney Disease May Dictate Cancer Risk

Posted 25 May 2014 by Drugs.com

THURSDAY, May 22, 2014 – Cancer risk for kidney transplant recipients may vary depending on the type of kidney disease they have, a new study finds. Patients with polycystic kidney disease (PKD), a genetic disorder, may be less likely to develop cancer than those with other types of kidney disease, but they still have a higher cancer risk than people in the general population, the researchers found. In polycystic kidney disease, cysts form in the kidneys, causing the kidneys to become enlarged. The condition affects nearly one in 1,000 people in the United States. The research team analyzed data from more than 10,000 Americans with polycystic kidney disease who received a kidney transplant and more than 107,000 transplant recipients with other kidney diseases. After adjusting for a number of factors, the researchers concluded that patients with polycystic kidney disease were 16 percent ... Read more

Related support groups: Cancer, Renal Cell Carcinoma, Chronic Kidney Disease, Polycystic Kidney Disease

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Wilms' Tumor, Cancer

Related Drug Support Groups

Provera, Depo-Provera, medroxyprogesterone, Avastin, Votrient, Tarceva, Sutent, Afinitor, Nexavar, view more... PegIntron, pazopanib, sunitinib, capecitabine, Opdivo, erlotinib, everolimus, bevacizumab, interferon alfa-2a, Torisel, sorafenib, Depo-Provera Contraceptive, Inlyta, Proleukin, peginterferon alfa-2b, depo-subQ provera 104, Roferon-A, axitinib, temsirolimus, aldesleukin, nivolumab, Cabometyx, Cycrin, Curretab, cabozantinib, Amen